FILING ANALYSIS · MONDAY, NOVEMBER 9
Tango Therapeutics, Inc. TNGX — 8-K: Results of Operations and Financial Condition
positive
Tango Therapeutics reported promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, with an 82% objective response rate and 88% 9-month progression-free survival rate, and plans to initiate a registrational Phase 3 study in 1H 2027. The company also has a strong cash position of $977.5 million as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →